Skip to main content
Aptabio Therapeutics Inc. logo

Aptabio Therapeutics Inc. — Investor Relations & Filings

Ticker · 293780 ISIN · KR7293780003 KO Manufacturing
Open in API
Filings indexed 209 across all filing types
Latest filing 2025-06-04 M&A Activity
Country KR South Korea
Listing KO 293780

About Aptabio Therapeutics Inc.

https://aptabio.com/

Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.

Recent filings

Filing Released Lang Actions
합병등종료보고서(합병)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Merger' (합병등종료보고서) filed by Aptabio Co., Ltd. It details the finalization of a merger with Objectivo Co., Ltd., including the timeline, shareholding changes, creditor protection, and post-merger financial summaries. This document is a formal regulatory filing regarding M&A activity completion. Since it specifically details the finalization of a merger transaction, it falls under the M&A Activity category.
2025-06-04 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically a decrease in holdings by '무림-오메가 신기술투자조합 1호' in '압타바이오(주)') due to conversion price adjustments and call option exercises. This falls under the category of Major Shareholding Notification (MRQ).
2025-05-28 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from Aptabio regarding the 'Adjustment of Conversion Price' for its convertible bonds. It details the specific changes to the conversion price and the number of convertible shares, citing market price fluctuations as the reason. This type of disclosure is a standard regulatory requirement for companies with outstanding convertible debt and falls under the category of capital structure updates.
2025-05-26 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming 'Corporate Day' investor relations event (IR 개최). It provides details such as the date, location, target audience, and purpose of the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a general regulatory filing/announcement.
2025-05-19 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the 17th fiscal period (2025-01-01 to 2025-03-31) submitted to the Financial Services Commission and Korea Exchange. It contains detailed financial data, business descriptions, and management analysis, which fits the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
주요사항보고서(제3자의전환사채매수선택권행사)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Services Commission (금융위원회) in South Korea. It specifically details the exercise of a call option on convertible bonds (제3자의 전환사채매수선택권 행사) by a third party. This type of filing relates to capital structure changes and financing activities. Since it does not fit into specific categories like 'Share Issue' (SHA) or 'M&A' (TAR) perfectly, and is a formal regulatory disclosure of a corporate event, it is best classified as a Regulatory Filing (RNS).
2025-05-12 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.